ISIS Pharmaceuticals (ISIS) Posts Quarterly Results

Share on StockTwits

ISIS Pharmaceuticals (NASDAQ:ISIS) announced its earnings results on Monday. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.02, StockRatingsNetwork reports. The company had revenue of $57.08 million for the quarter, compared to the consensus estimate of $45.60 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. The company’s revenue for the quarter was up 49.8% on a year-over-year basis.

In other ISIS Pharmaceuticals news, CEO Stanley T. Crooke unloaded 16,000 shares of ISIS Pharmaceuticals stock on the open market in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $30.53, for a total transaction of $488,480.00. The transaction was disclosed in a filing with the SEC, which is available at this link.

Shares of ISIS Pharmaceuticals (NASDAQ:ISIS) opened at 30.40 on Monday. ISIS Pharmaceuticals has a 52-week low of $22.25 and a 52-week high of $62.66. The stock has a 50-day moving average of $32.45 and a 200-day moving average of $38.23. The company’s market cap is $3.574 billion.

A number of research firms have recently commented on ISIS. Analysts at Zacks reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Thursday, June 5th. They now have a $29.00 price target on the stock. On a related note, analysts at Summer Street reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Friday, May 23rd. Finally, analysts at TheStreet downgraded shares of ISIS Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and five have assigned a buy rating to the stock. ISIS Pharmaceuticals currently has an average rating of “Hold” and an average target price of $41.10.

Receive News & Ratings for ISIS Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ISIS Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.

Latest News

Michigan Pondering Ban on Tesla
Michigan Pondering Ban on Tesla
Train Drivers in Germany Call Two-Day Strike
Train Drivers in Germany Call Two-Day Strike
Deadline Passes, No Word on Hostages Held in Philippines
Deadline Passes, No Word on Hostages Held in Philippines
Netflix Monthly Price Hike Weighs Down Growth
Netflix Monthly Price Hike Weighs Down Growth
Qualcomm Acquiring Chipmaker in the UK
Qualcomm Acquiring Chipmaker in the UK
Burberry Sales Up in First Half, but Market is Much Tougher
Burberry Sales Up in First Half, but Market is Much Tougher


Leave a Reply

 
Advertisement
Advertisement
© 2006-2014 WKRB News.